Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

Kimberley Hanson, Stephen D. Robinson, Karamallah Al-Yousuf, Adam E. Hendry, Darren W. Sexton, Victoria Sherwood (Lead / Corresponding author), Grant N. Wheeler

Research output: Contribution to journalArticle

58 Downloads (Pure)

Abstract

[This corrects the article DOI: 10.18632/oncotarget.23378.].

Original languageEnglish
Pages (from-to)36645
Number of pages1
JournalOncotarget
Volume9
Issue number93
Publication statusPublished - 27 Nov 2018

Fingerprint

leflunomide
Antirheumatic Agents
Mitogen-Activated Protein Kinase Kinases
Melanoma
Growth

Cite this

Hanson, K., Robinson, S. D., Al-Yousuf, K., Hendry, A. E., Sexton, D. W., Sherwood, V., & Wheeler, G. N. (2018). Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget, 9(93), 36645.
Hanson, Kimberley ; Robinson, Stephen D. ; Al-Yousuf, Karamallah ; Hendry, Adam E. ; Sexton, Darren W. ; Sherwood, Victoria ; Wheeler, Grant N. / Correction : The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. In: Oncotarget. 2018 ; Vol. 9, No. 93. pp. 36645.
@article{26f10f4045f849129b6f43affa9717c4,
title = "Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth",
abstract = "[This corrects the article DOI: 10.18632/oncotarget.23378.].",
author = "Kimberley Hanson and Robinson, {Stephen D.} and Karamallah Al-Yousuf and Hendry, {Adam E.} and Sexton, {Darren W.} and Victoria Sherwood and Wheeler, {Grant N.}",
year = "2018",
month = "11",
day = "27",
language = "English",
volume = "9",
pages = "36645",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "93",

}

Hanson, K, Robinson, SD, Al-Yousuf, K, Hendry, AE, Sexton, DW, Sherwood, V & Wheeler, GN 2018, 'Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth', Oncotarget, vol. 9, no. 93, pp. 36645.

Correction : The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. / Hanson, Kimberley; Robinson, Stephen D.; Al-Yousuf, Karamallah; Hendry, Adam E.; Sexton, Darren W.; Sherwood, Victoria (Lead / Corresponding author); Wheeler, Grant N.

In: Oncotarget, Vol. 9, No. 93, 27.11.2018, p. 36645.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correction

T2 - The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

AU - Hanson, Kimberley

AU - Robinson, Stephen D.

AU - Al-Yousuf, Karamallah

AU - Hendry, Adam E.

AU - Sexton, Darren W.

AU - Sherwood, Victoria

AU - Wheeler, Grant N.

PY - 2018/11/27

Y1 - 2018/11/27

N2 - [This corrects the article DOI: 10.18632/oncotarget.23378.].

AB - [This corrects the article DOI: 10.18632/oncotarget.23378.].

M3 - Article

C2 - 30564304

VL - 9

SP - 36645

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 93

ER -

Hanson K, Robinson SD, Al-Yousuf K, Hendry AE, Sexton DW, Sherwood V et al. Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget. 2018 Nov 27;9(93):36645.